Setting the record straight on rosuvastatin

Teva Canada the first to litigate

The following timeline offers an accurate picture of how Teva Canada led the way through every stage to deliver this high-quality medicine to Canadian consumers and our customers eight years before patent expiry—which will save the healthcare system an estimated total of $3.4 billion.

Generics

Court File No.

Start Date

No. of Months after Teva

End Date

No. of Months the Case Was Active

Teva

T-1636-08

2008-10-23

0

2010-07-29

21.25

Application was heard on 2010-03-22.

Application with respect to the formulation patent (’783) was dismissed on 2010-03-25.

Apotex

T-1972-08

2008-12-22

2

2010-07-29

19.25

Apotex requested a hearing adjacent to Teva’s.

Application was heard on 2010-03-29, on the heels of Teva’s hearing.

No dismissal decision on any patent.

Cobalt

T-780-09

2009-05-14

6.75

2010-12-06

18.75

Application was set for a hearing on 2010-11-29.

Application was adjourned without being heard.

Sandoz

T-1074-09

2009-07-02

8.25

2011-01-27

18.75

Application was set for a hearing on 2011-04-11.

On 2010-04-26, the application with respect to the formulation patent (’783) was dismissed (as a result of Teva’s success).

Application was adjourned without being heard.

PMS

T-528-10

2010-04-07

17.5

2012-03-16

23.25

Application was heard on 2012-01-09.

Application was dismissed shortly afterward without a decision being rendered.

Ranbaxy

T-1367-10
T-1368-10
T-1369-10

2010-08-26

22

2011-09-19

12.75

Application in early stages.

Application stayed shortly after commencement.

Mylan

T-1535-10

2010-09-24

23

2011-04-19

6.75

Application in early stages.

Application stayed shortly after commencement.

Riva

T-1249-11
T-1250-11

2011-07-29

33.25

2011-11-09

3.25

Shortly after commencement, the application was discontinued on 2011-11-09.